ProShares Ultra NASDAQ Biotechnology
26 hedge funds and large institutions have $7.07M invested in ProShares Ultra NASDAQ Biotechnology in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
69% less capital invested
Capital invested by funds: $22.9M → $7.07M (-$15.9M)
Holders
26
Holding in Top 10
–
Calls
$4M
Puts
$2.23M
Top Buyers
| 1 | +$522K | |
| 2 | +$261K | |
| 3 | +$238K | |
| 4 |
Morgan Stanley
New York
|
+$79.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$79K |
Top Sellers
| 1 | -$3.87M | |
| 2 | -$2.4M | |
| 3 | -$1.54M | |
| 4 |
Jane Street
New York
|
-$1.5M |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$953K |